Research News and Research

RSS

Innate Therapeutics initiates MIS416 Phase 2a clinical study in patients with progressive multiple sclerosis

Innate Therapeutics today announced that the company has begun treating patients in a Phase 2a clinical study of its lead molecule, MIS416, in patients with progressive multiple sclerosis (MS).

11 Oct 2010

Micromet to initiate MEDI-565 Phase 1 trial in patients with advanced gastrointestinal cancer

Micromet, Inc. today announced that its licensee for MT111, MedImmune, plans to initiate a Phase 1 trial in patients with advanced gastrointestinal cancers based on an investigational new drug (IND) application recently accepted by the U.S. Food and Drug Administration (FDA).

11 Oct 2010

The insurance straw man

In this Kaiser Health News column, James C. Capretta of the Ethics and Public Policy Center criticizes Health and Human Services Secretary Kathleen Sebelius for some of her tough tactics with insurance companies.

11 Oct 2010

AVEO presents tivozanib Phase 2 study results at ESMO Congress

AVEO Pharmaceuticals, Inc. a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC) were presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.

11 Oct 2010

Geron commences GRNOPC1 hESC-based cell therapy in patients with spinal cord injury

Geron Corporation today announced the enrollment of the first patient in the company's clinical trial of human embryonic stem cell (hESC)-derived oligodendrocyte progenitor cells, GRNOPC1. The primary objective of this Phase I study is to assess the safety and tolerability of GRNOPC1 in patients with "complete" American Spinal Injury Association (ASIA) Impairment Scale grade A thoracic spinal cord injuries. Participants in the study must be newly injured and receive GRNOPC1 within 14 days of the injury.

11 Oct 2010

The Atlantic reports on potential challenges to passage of the International Violence Against Women Act

The Atlantic looks at the challenges facing the passage of I-VAWA (S.2982, HR. 4594), or the International Violence Against Women Act, which was recently delayed in Congress.

11 Oct 2010

Researchers to convene for 2010 Advances in Breast Cancer Research Workshop at University of Arkansas

Leading national researchers in the fight against breast cancer will convene Oct. 26-29 for the 2010 Advances in Breast Cancer Research Workshop at the University of Arkansas. More than 70 scientists from diverse research areas in science, medicine, engineering and technology will participate. Ten featured speakers will present cutting-edge research on breast cancer diagnosis, therapeutic techniques, treatment and screening.

11 Oct 2010

NIH selects Neil Chi for 2010 New Innovator Award

The National Institutes of Health has chosen Neil Chi, MD, PhD, assistant professor of medicine in the division of cardiology at the University of California, San Diego, as one of its 2010 NIH Director's New Innovator Award recipients.

11 Oct 2010

Weikang Bio-Technology reiterates fiscal 2010 revenue guidance, targets growth of 30% to 50% for fiscal 2011

Weikang Bio-Technology Group Co., Inc., a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that the Company is reiterating its fiscal 2010 revenue guidance of $55 million, net profit of $21 million and earning per share of $0.75.

11 Oct 2010

Valeant announces Alexza's receipt of FDA CRL for AZ-004 NDA

Valeant Pharmaceuticals International, Inc. announced today that Alexza Pharmaceuticals, Inc. has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding Alexza's New Drug Application (NDA) for AZ-004 (Staccato® loxapine) submitted as Adusuve™ Staccato® (loxapine) inhalation aerosol, 5 mg and 10 mg.

11 Oct 2010

Novel hormonal treatments may help ER-negative breast cancer patients: Study

Women who have estrogen (ER) negative breast cancer may have more drug treatment options than previously thought, a Creighton (pronounced Cray-ton) University study suggests. The study is reported in the Oct. 11 online version of the journal Oncogene.

11 Oct 2010

The age wave could bust government budgets, rating agency says

The ratings agency Standard & Poor's has joined the chorus of concern about how the looming age wave will affect governments that must pay for escalating entitlement programs, The Wall Street Journal reports.

11 Oct 2010

Sec. of State Clinton, other officials launch initiative to provide mobile phones to 150M women in the developing world

Officials gathered in Washington, D.C. on Thursday to launch mWomen, an initiative aimed at increasing access to mobile phones to further health and development benefits among women in the developing countries, the Telegraph reports.

11 Oct 2010

Part of brain reorganizes to enhance visual abilities in deaf cats

Deaf or blind people often report enhanced abilities in their remaining senses, but up until now, no one has explained how and why that could be. Researchers at The University of Western Ontario, led by Stephen Lomber of The Centre for Brain and Mind have discovered there is a causal link between enhanced visual abilities and reorganization of the part of the brain that usually handles auditory input in congenitally deaf cats. The findings, published online in Nature Neuroscience, provide insight into the plasticity that may occur in the brains of deaf people.

11 Oct 2010

First Edition: October 11, 2010

Today's early morning highlights include articles on new options for open season, concerns among retirees about the provisions of the federal health law and the latest campaign arguments over that new overhaul.

11 Oct 2010

NIH awards La Jolla Institute $12.6M to develop San Diego's first Center for RNAi screening

The La Jolla Institute for Allergy & Immunology will develop San Diego's first Center for RNAi screening -- a breakthrough genomics technology that will further enhance San Diego's reputation as a national research leader and provide the local biomedical community ready access to the Nobel-Prize winning technology.

11 Oct 2010

ESMO and Thomson Reuters launch unique portal for oncologists

A unique portal, offering oncologists access to the latest information in the field of cancer research, will be launched in 2011 by the European Society for Medical Oncology (ESMO) in association with Thomson Reuters. The announcement was made today at the 35th ESMO Congress taking place from 8 to 12 October, in Milan, Italy.

11 Oct 2010

New natural dietary components inhibit breast cancer cells

Researchers at Indiana University and Methodist Research Institute have published the dramatic effects of a natural formula against breast cancer. The impressive results are found in the most recent publication of Integrative Cancer Therapies. Lead investigator Dr. Daniel Sliva says, The formula we studied inhibits growth of highly metastatic human breast cancer cells, and suppresses metastatic potential of these cells.

11 Oct 2010

$Balloon kyphoplasty offers effective relief for debilitating spinal fractures suffered by metastatic cancer patients$

Balloon kyphoplasty offers effective relief for debilitating spinal fractures suffered by metastatic cancer patients

A surgical technique appears to offer quick and effective relief for debilitating spinal fractures often suffered by patients with metastatic cancer, researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan.

11 Oct 2010

Combination of MET and erlotinib delays lung cancer progression: Study

A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial show.

11 Oct 2010

Research News and Research

Innate Therapeutics initiates MIS416 Phase 2a clinical study in patients with progressive multiple sclerosis

Micromet to initiate MEDI-565 Phase 1 trial in patients with advanced gastrointestinal cancer

The insurance straw man

AVEO presents tivozanib Phase 2 study results at ESMO Congress

Geron commences GRNOPC1 hESC-based cell therapy in patients with spinal cord injury

The Atlantic reports on potential challenges to passage of the International Violence Against Women Act

Researchers to convene for 2010 Advances in Breast Cancer Research Workshop at University of Arkansas

NIH selects Neil Chi for 2010 New Innovator Award

Weikang Bio-Technology reiterates fiscal 2010 revenue guidance, targets growth of 30% to 50% for fiscal 2011

Valeant announces Alexza's receipt of FDA CRL for AZ-004 NDA

Novel hormonal treatments may help ER-negative breast cancer patients: Study

The age wave could bust government budgets, rating agency says

Sec. of State Clinton, other officials launch initiative to provide mobile phones to 150M women in the developing world

Part of brain reorganizes to enhance visual abilities in deaf cats

First Edition: October 11, 2010

NIH awards La Jolla Institute $12.6M to develop San Diego's first Center for RNAi screening

ESMO and Thomson Reuters launch unique portal for oncologists

New natural dietary components inhibit breast cancer cells

Balloon kyphoplasty offers effective relief for debilitating spinal fractures suffered by metastatic cancer patients

Combination of MET and erlotinib delays lung cancer progression: Study

A guide to advancing biotherapeutic research eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Improving healthcare sustainability through carbon data